OCERA THERAPEUTICS, INC. (NASDAQ:OCRX) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
release announcing its financial results and other information
for the quarter and year ended December 31, 2016. The full text
of the press release and the related attachments are furnished as
Exhibit 99.1 hereto and incorporated herein by reference.
attached hereto, is intended to be furnished and shall not be
deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or otherwise
subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except
as expressly set forth by specific reference in such filing.
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press Release of Ocera Therapeutics, Inc. dated March
10, 2017, furnished hereto. |
About OCERA THERAPEUTICS, INC. (NASDAQ:OCRX)
Ocera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. It is conducting a randomized, placebo-controlled double blind Phase IIb clinical trial to evaluate the efficacy of intravenous administration of OCR-002 IV formulation in reducing the severity of HE symptoms among HE patients. The Company also conducted a Phase IIa investigator-sponsored trial of OCR-002 in Spain in patients with upper gastrointestinal bleeding associated with liver cirrhosis. It is developing an oral form of OCR-002 to provide continuity of care for HE patients, where the intravenous form is used for hospital-based acute care and the oral form for chronic maintenance care post discharge. OCERA THERAPEUTICS, INC. (NASDAQ:OCRX) Recent Trading Information
OCERA THERAPEUTICS, INC. (NASDAQ:OCRX) closed its last trading session 00.00 at 1.89 with 49,735,345 shares trading hands.
